Habilidades en patología cardiovascular:
Manejo de la insuficiencia cardiaca con función sistólica preservada

 

BIBLIOGRAFÍA GENERAL

· Remme WJ, Swedberg K. The Task Force on Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527-60.

· Hunt HA, Baker DW, Chin MH, Cinquegrani MP, Feldmanmd AM, Francis GS et al. American College of Cardiology/American Heart Association Guidelines for the Evaluation and Management of Chronic Heart Failure in the adult. Circulation 2002: 104 (24) 2996-3007.
· Feigenbaum H. Valoración ecocardiográfica del ventrículo izquierdo. En: Feigenbaum H, editor. Echocardiography. Philadelphia: Lea & Febiger, 1994; 134-151.
· Choong CY. Left Ventricle and Diastolic function. Its principles and evaluation. En: Weyman AE, editor. Principles and practice of Echocardiography. Philadelphia: Lea & Febiger, 1994; 721-780
· Grupo de Trabajo de Insuficiencia Cardíaca de la SEMI. Insuficiencia Cardíaca: recomendaciones diagnósticas y terapéuticas de la Sociedad Española de Medicina Interna. Jarpyo: Madrid, 2005.
·
· Braunwald et al. Heart failure. En: Braunwald´s heart disease. A textbook on cardiovascular medicine. Zipes D, Libby P, Bonow R, Braunwald E. editores. Saunders. Philadelphia, 2005: 457-652
· 7.- Grupo de trabajo de IC de la SEMI. La IC en los Servicios de M. Interna en España. Registro SEMI-IC Med Clin 2002;118,605-610.
· 8.- Senni M, Tribouilloy CN, Rodeheffer RJ et al.
Congestive Heart Failure in the Community : A Study of All Incident Cases in Olmsted County, Minnesota, in 1991
Circulation 1998; 98: 2282 - 89.
· 9.- Angeja BG, Grossman W.
Evaluation and Management of Diastolic Heart Failure
Circulation 2003; 107: 659 - 663.
· 10.- Vasan RS, Levy D.
Defining Diastolic Heart Failure : A Call for Standardized Diagnostic Criteria
Circulation, May 2000; 101: 2118 - 2121.
· 11.- Gandhi SK, Powers JC, Nomeir AM, et al.The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med. 2001;344:17-22.

· 12.- Wang TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS et al.
Natural History of Asymptomatic Left Ventricular Systolic Dysfunction in the Community. Circulation 2003; 108: 977 - 982.

· 13.- Osca J, Quesada A, Arnau MA, y cols. Péptido cerebral natriurético. Valor diagnóstico en la Insuficiencia Cardiaca. Rev Esp Cardiol 2002; 55(1): 7-15

· Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R, Gardetto N, Wanner E, Maisel A. Utility of B-Type-Natriuretic peptide Detecting Diastolic Dysfunction. Comparison with Doppler Velocity Recorsings. Circulation 2002;105:595-601

· Maisel A. B-Type Natriuretic Peptide Levels: A Potencial Novel "White Count" for Congestive Herat Failure. J Card Fail 2001;7: 183-193
· McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, Tunstall-Pedoen H, McMurray JJV, Dargie HJ. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351: 9-13
· 14.- Davidson NC, Struthers A. D. The ABC of natriuretic peptides. Pathophysiology, diagnosis and therapeutic potential. In: Heart Failure in clinical practice. MacMurray JJV and Cleland J, Eds. Martín Dunitz Ltd. London. 2000:59-72
· 15.-NICE Guidelines. The National Collaborating Centre for Chronic Conditions. Chronic heart failure. National clinical guideline for diagnosis and management in primary and secondary care, 2003.

· 16.- Morrison LK, Harrison A, Krishnaswamy P,et al. Utility of a rapid B-natriuretic peptideassay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol. 2002;39:202-209.

· 17.- Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV et al for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777-81

· 18.- Lobos JM, Mena A, Díaz S, Casas J, González AI, Lozano L, Vegas T. Guía clínica sobre insuficiencia cardiaca crónica. FMC- Protocolos 2002/2.

· 19.- Abrams J. Nitroglycerin and long-acting nitrates in clinical practice. Am J Med 1983; 74: 85-94.

· 20.- Lobos JM, González A, Blasco A, Mena A, Castellanos A, Díaz S et al. Cardiopatía Isquémica. Diagnóstico y tratamiento de la angina estable. FMC 2003; 10 (Suppl 2): 7-34.

· 21.- Díaz-Sánchez S, Lobos JM, Conthe P, González A, Ortigosa J. Manual de Práctica Clínica. Cardiopatía Isquémica. Doyma Ed. Madrid 2000.

· 22.- Brophy JM, Joseph L, Rouleau JL. Beta-blokers in congestive Heart Failure. A Bayesian meta-analysis. Ann Intern Med 2001; 134: 550-560.
· Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, et al, for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
· 24.- Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beepers G, De Faire U, et al, for the LIFE study group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10.

· 25.- Wachtell K, Bella JN, Rokkedal J et al. Change in diastolic left ventricular filling alter one year of antihypertensive treatment. The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study. Circulation 2002; 105: 1-6.

· 26.- I Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray J, Michelson E et al for the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-766.

· 27.- The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with Heart Failure. N Engl J Med 1997;336:525-33.

· 28.- . Eichhorn EJ, Gheorghiade M. Digoxin. New perspective on an old drug. N Engl J Med 2002;347:1394-5.

 

volver